MPE Inc. Launches New Capital Medical Equipment Commercialization Platform
Commercialization platform reduces costs and eliminates risks for leading MedTech OEMs when designing, developing and manufacturing medical devices.
MPE Inc.'s unified capital equipment commercialization platform has been purpose-built to redefine the MedTech development and manufacturing industry, offering clients the benefits of working with an onshore, integrated organization that can infuse compliance, differentiation and adoption readiness into every stage of the product life cycle.
MPE Inc. has combined the most critical control planes of compliance, differentiation, and adoption readiness under one platform to bring products to market faster and reduce the risks associated with legacy, siloed contract manufacturing operations that MedTech companies have been increasingly burdened with as the healthcare market rapidly changes.
"We've worked for years to purpose-build this solution and our customers have experienced great results", says President & CEO,
Visit the new www.mpe-inc.com to learn more about MPE Inc.'s capital medical equipment commercialization platform and how it supports MedTech OEMs achieve growth.
About MPE
MPE has developed the only capital equipment commercialization platform that enables healthcare and technology OEMS to scale, integrate, and extend their medical device commercial strategies. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/mpe-inc-launches-new-capital-medical-equipment-commercialization-platform-302035921.html
SOURCE MPE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
- FLSmidth: Transactions under share buy-back programme
- Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share